Product
Single target immunomodulation
1 clinical trial
1 indication
Indication
COVID-19 ARDSClinical trial
Personalized Targeted Immunomodulation in Patients With ARDS Related to COVID19 and Future Pandemic PathogensStatus: Completed, Estimated PCD: 2022-02-01